Journal
ONCOIMMUNOLOGY
Volume 1, Issue 5, Pages 579-580Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/onci.20730
Keywords
-
Categories
Ask authors/readers for more resources
Human cancers carry hundreds of non-synonymous mutations, several dozens among which may lead to the generation of tumor-specific MHC Class I-restricted epitopes. Hence every patient's tumor harbors a highly specific mutational and antigenic signature and up to 95% of these mutations are unique. This mutanome can be identified by deep sequencing and can be subjected to systematic analyses of the immunogenicity of mutated proteins/peptides. We anticipate that this approach will lead to individualized immunotherapies by means of tailored vaccines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available